Neuregenix Ltd is a leading brand that specializes in offering vital neurobiological support for neural repair and axon regeneration-related drug discovery programs. Founded in 2007 by Professor Martin Berry, Dr. Zubair Ahmed, and a team of dedicated neuroscientists, Neuregenix aims to enhance the impact of their cutting-edge research in neurotrauma and neurodegeneration.

With over 11 years of experience, Neuregenix has established itself as a niche Contract Research Organization (CRO) in the neurological and ophthalmology research fields. They collaborate with world-class experimental and clinical research scientists, as well as opinion leaders, to provide a comprehensive range of services to the biotechnology and pharmaceutical industry worldwide. Their services include drug discovery, preclinical drug screening, and clinical trial services.

Neuregenix takes pride in the direct links they forge between their scientists and customers, ensuring a fruitful working relationship. With recognized expertise, highly motivated staff, and a commitment to quality, Neuregenix is a trusted partner for all neurobiological research needs